Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder

Apixaban is an oral small‐molecule, direct factor Xa (FXa) inhibitor approved in adults for treatment of deep vein thrombosis and pulmonary embolism, and for reducing risk of venous thromboembolism recurrence after initial anticoagulant therapy. This phase I study (NCT01707394) evaluated the pharmac...

Descripción completa

Detalles Bibliográficos
Autores principales: Merali, Samira J., Byon, Wonkyung, Patel, Yogesh T., Elsrougy, Amira, Marchisin, David, Perera, Vidya, Chen, Weidong, He, Bing, Murthy, Bindu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088081/
https://www.ncbi.nlm.nih.gov/pubmed/36861188
http://dx.doi.org/10.1002/psp4.12935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088081/
https://www.ncbi.nlm.nih.gov/pubmed/36861188
http://dx.doi.org/10.1002/psp4.12935

Ejemplares similares